Retatrutide vs Tirzepatide: What's the Difference?

Quick Overview

The key difference: Retatrutide adds glucagon receptor activity to the GLP-1/GIP combination. This third target may enhance fat burning and produce more weight loss, but the medication is still being studied.

For background on each medication individually, see what is tirzepatide and what is retatrutide.

Triple vs Dual Action

Tirzepatide (dual agonist):

• GLP-1: Reduces appetite, slows gastric emptying, improves blood sugar
• GIP: Enhances satiety, improves metabolic function

Retatrutide (triple agonist):

• GLP-1: Same appetite and blood sugar effects
• GIP: Same satiety and metabolic effects
• Glucagon: May increase energy expenditure and enhance fat burning

The glucagon component is what sets retatrutide apart. Glucagon traditionally raises blood sugar by releasing stored glucose from the liver. However, it also increases metabolic rate and may directly promote fat breakdown.

The concern with adding glucagon was that it might cause blood sugar to rise. However, in trials, the GLP-1 and GIP effects counterbalanced this, and blood sugar actually improved.

Clinical Trial Results

Tirzepatide (Phase 3 clinical trials):

• 15mg dose: Significant weight loss at the highest dose
• About 36% of participants lost more than 25% of body weight
• Robust improvements in metabolic markers

Retatrutide (Phase 2 trial):

• 12mg dose: 24.2% average weight loss
• About 26% of participants lost more than 30% of body weight
• Weight loss was still continuing at study end

Important caveat: These numbers aren't directly comparable. The retatrutide data is from Phase 2 trials (smaller, earlier studies), while tirzepatide data is from Phase 3 trials (larger, more rigorous). Phase 3 results for retatrutide may differ.

That said, the 24% average weight loss in Phase 2 is impressive. If Phase 3 confirms these results, retatrutide would be the most effective weight loss medication ever studied.

Side Effects

Both medications share similar GI side effects:

• Nausea (common, especially during dose escalation)
• Diarrhea
• Vomiting
• Constipation
• Decreased appetite

In the Phase 2 trial, retatrutide's side effect rates were comparable to tirzepatide. The glucagon component didn't appear to add significant new side effects.

Both medications require gradual dose escalation to minimize these effects. See managing nausea with GLP-1 medications for tips.

Availability

Tirzepatide: Approved and available. In Nigeria, compounded tirzepatide is accessible through proper medical channels. See how to get GLP-1 medications.

Retatrutide: Not yet approved. Currently in Phase 3 clinical trials. Expected timeline:

• Phase 3 results: Late 2026 or 2027
• FDA approval: 2027-2028 if trials succeed
• Nigerian availability: Likely 1-2 years after major market approval

For now, tirzepatide is the strongest available option. Retatrutide is promising but not yet accessible outside of clinical trials.

Which to Choose?

Choose tirzepatide if:

• You want to start treatment now
• You want a medication with established safety data
• You prefer a medication that's already approved

Consider waiting for retatrutide if:

• You're not in a rush and want maximum potential effect
• You've tried tirzepatide without adequate results
• You're comfortable with a newer medication

The practical answer: Start with what's available. Tirzepatide is highly effective and available now. If retatrutide proves superior when approved, you can always switch later.

There's no benefit to waiting years for a medication that may or may not be better when effective options exist today.